TNFRSF17 and neoplasm: In an open-label, multiple centres phase 1 clinical trial for treating relapsed or refractory MM with anti-BCMA CAR-T cells, the high clinical response rate was observed to be similar for both patients have less than 50% and more than 50% BCMA antigen expression level, which was consistent with their pervious in vitro results in killing a broad range of BCMA expressing tumour cell lines [15].